Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(75.0%)
Phase 2
2(25.0%)
8Total
N/A(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT00831350Phase 2Completed

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

Role: lead

NCT01025063Completed

Use of Spectral OCT in Combination Therapy

Role: lead

NCT01428388Not ApplicableCompleted

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Role: lead

NCT00406263Completed

Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectomy Surgery and Controls

Role: lead

NCT01410201Not ApplicableTerminated

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Role: lead

NCT01282411Completed

Anatomic Outcomes Following Ozurdex Injections

Role: lead

NCT00546936Phase 2Unknown

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Role: lead

NCT00455871Not ApplicableUnknown

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

Role: lead

NCT00409669Not ApplicableUnknown

Intraocular Pressure Accuracy and Variability of the Barraquer Tonometer

Role: lead

NCT00459849Not ApplicableUnknown

Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma

Role: lead

NCT00272766Not ApplicableTerminated

Macugen for Histoplasmosis

Role: lead

All 11 trials loaded